Alcon Inc. (ALC)
NYSE: ALC · Real-Time Price · USD
87.87
+0.32 (0.37%)
Aug 1, 2025, 4:00 PM - Market closed
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Achilles Therapeutics stock have a consensus rating of "Buy" and an average price target of $106.88, which forecasts a 21.63% increase in the stock price over the next year. The lowest target is $84 and the highest is $120.
Price Target: $106.88 (+21.63%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Achilles Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 4 | 3 | 3 | 2 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $90 → $84 | Hold | Maintains | $90 → $84 | -4.40% | Jul 15, 2025 |
| Needham | Needham | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +25.18% | May 14, 2025 |
| Keybanc | Keybanc | Buy Maintains $108 → $112 | Buy | Maintains | $108 → $112 | +27.46% | Mar 31, 2025 |
| Mizuho | Mizuho | Buy Maintains $115 → $120 | Buy | Maintains | $115 → $120 | +36.57% | Mar 28, 2025 |
| Needham | Needham | Strong Buy Maintains $107 → $110 | Strong Buy | Maintains | $107 → $110 | +25.18% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
10.58B
from 9.91B
Increased by 6.75%
Revenue Next Year
11.38B
from 10.58B
Increased by 7.60%
EPS This Year
3.29
from 2.05
Increased by 60.72%
EPS Next Year
3.83
from 3.29
Increased by 16.11%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.2B | 12.2B | 13.3B | ||
| Avg | 10.6B | 11.4B | 12.2B | ||
| Low | 10.2B | 10.8B | 11.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.9% | 15.6% | 16.5% | ||
| Avg | 6.8% | 7.6% | 6.7% | ||
| Low | 2.5% | 1.7% | 0.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.13 | 4.66 | 4.92 | ||
| Avg | 3.29 | 3.83 | 4.30 | ||
| Low | 3.10 | 3.43 | 3.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.3% | 41.4% | 28.7% | ||
| Avg | 60.7% | 16.1% | 12.4% | ||
| Low | 51.1% | 4.1% | -1.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.